535-P: Relationship between Renal Capacities to Reabsorb Glucose and Kidney Disease in Patients with Diabetes

Hyperglycemia can impair tubulo-glomerular balance and cause kidney disease by opening pre-glomerular resistances. Susceptibility to kidney disease is heterogeneous among diabetic patients, and renal capacities to reabsorb glucose may contribute to it. We studied if renal capacities to reabsorb glucose relate to kidney disease in diabetic patients. The diabetic patients attending over 6 months our tertiary referral center in Paris, France (where SGLT2 inhibitors are not available), were studied consecutively for their fractional glucose reabsorption (1-[urinary glucose x plasma creatinine]/[urinary creatinine x plasma glucose]) according to their glycemia ( 11mM), and kidney disease (normo-, micro-, macroalbuminuria, and estimated Glomerular Filtration Rate (eGFR, CKP-EPI equation) >90, 90-60, 59-30, and 2 ; patients with eGFR ≤15ml/min/1.73m 2 were excluded). Of 637 participants, 106 displayed glycemia 11mM. Fractional glucose reabsorption was similar in participants with glycemia 11mM, proportional to kidney disease: normoalbuminuria (n=135) 93.50 (81.60-99.34)%, microalbuminuria (n=77) 96.56 (93.77-99.71)%, macroalbuminuria (n=31) 99.12 (94.20-99.64)% (p 90ml/min/1.73m 2 (n=111) 94.13 (82.34-98.58)%, 90-60ml/min/1.73m 2 (n=72) 96.35 (87.81-99.75)%, 59-30ml/min/1.73m 2 (n=46) 98.88 (92.19-99.78)%, 2 (n=14), 99.11 (97.57-99.77)% (p 11mM contributed independently to their urinary albumin excretions and eGFR values. Renal capacities to reabsorb glucose were linked to kidney disease in diabetic patients with glycemia >11mM. Inter-individual capacities to reabsorb glucose may contribute to kidney disease of diabetic patients. Disclosure O. Matar: None. L. Potier: Advisory Panel; Self; Merck Sharp & Dohme Corp. Consultant; Self; Sanofi. Y. Abouleka: None. F. Fumeron: None. K. Mohammedi: None. S. Hadjadj: Consultant; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A/S, Sanofi, Servier. Research Support; Self; Bayer AG, Janssen Research & Development. Speaker9s Bureau; Self; Abbott, Valbiotis. R. Roussel: Advisory Panel; Self; Merck Sharp & Dohme Corp., Sanofi. Consultant; Self; Abbott, AstraZeneca, Eli Lilly and Company, Medtronic, Novo Nordisk A/S, Physiogenex. Research Support; Self; Janssen Pharmaceuticals, Inc. G. Velho: None. M. Marre: Advisory Panel; Self; Servier. Board Member; Self; Merck Sharp & Dohme Corp., Novo Nordisk A/S.